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The introduction of hybridoma technology has created
renewed interest in the possibility of using antibodies in the
treatment of cancer. Used alone monoclonal antibodies
(McAbs) have only occasionally produced significant
remission in patients (Miller et al., 1982). However, as
carriers for cytotoxic levels of radionuclides they are showing
considerable promise (Carrasquillo et al., 1984; Epenetos,
1985). Polyclonal antibodies have for some time been used in
this way by Order and his colleagues in Baltimore. In recent
years they have been reporting remissions with 131I-labelled
polyclonal antibody in the treatment of primary liver
tumours (Order et al., 1980, 1985). There are many research
groups now examining the capacity of McAbs to act as
carriers for drugs, toxins and radionuclides and although
they offer a very useful means of transporting cytotoxic
agents preferentially to tumours there are a number of
difficulties. For example, while still in the blood injected
McAb can complex with circulating tumour antigen, or with
host immunoglobulin directed against the McAb- thereby
reducing the amount of cytotoxic agent available to the
tumour. Even when the combined antibody-cytotoxic agent
has successfully passed through the capillary wall and into
the tumour, diffusion* to those cells farthest from the
capillary will be impaired by the large size of the carrier
molecule and possibly because of competition from binding
sites on those cells closest to the capillary. The present work
was designed to obtain more information with respect to the
latter problem, using lymphoma in the mouse spleen as a
model.
In outline the project consisted of inoculating mice with
lymphoma cells and when the tumour had reached the stage
at which there were discrete intrasplenic masses 1251I-labelled
tumour specific antibody was injected i.v. and the animals
killed at intervals, the spleen removed, and autoradiographs
(ARGs) prepared. The distribution of activity in the ARGs
was studied and compared with that of ARGs from similar
lymphomatous animals in which a '251-labelled non-specific
antibody had been injected and the animals killed after the
same intervals.
The animal model was a T cell lymphoma (A120) which
bears a high surface membrane density of Thy 1.1 antigen
(epitope density -3 x 105cell-1, our unpublished results).
The lymphoma had been induced by repeated whole body X-
irradiation of A.Thy-
Ia/Ola mice and at the time of
experimentation the tumour was at passage 20. In order
that the lymphoma cells should have in effect a tumour-
specific antigen the A120 cells were implanted into congenic
A/J/Ola mice in which the Thy 1.1 antigen in all tissues was
replaced by the allelic form Thy 1.2. Therefore the only
Thy 1.1 antigen in the lymphomatous mice was on the A120
cells. The Thy 1.1 antigen on these cells is seen by the
monoclonal antibody MRC OX7 (IgG,), produced by a
hybridoma line kindly donated by Dr A.F. Williams
(Oxford). Our control IgG, monoclonal antibody (H17E2)
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*For the purpose of this paper diffusion includes the transport of
antibody by the mass movement of intercellular fluid (convection).
did not see epitopes on A120. H17E2 sees an epitope on
human placental and testicular alkaline phosphatase and on
a number of human tumour types (Travers & Bodmer,
1984). It was kindly supplied by Dr D. Tucker (London).
Both antibodies were labelled by a modification of the
Chloramine T method (Hunter & Greenwood, 1962); 75 kBq
1 251ug I antibody.
Twelve mice were injected i.v. with 105 A120 cells and
after 12-14 days 6 of them were injected i.v. with 80,ug each
1251-labelled specific antibody MRC OX7, and 6 with 80,ig
each of 125I-labelled non-specific antibody H17E2.
At each of the time intervals, Omin, 30min and 4h, after
injection of the labelled antibodies 2 mice were killed from
each of the MRC OX7 and H17E2 groups. The mice were
killed by i.v. injection of sodium pentobarbitone and in the
case of the time zero mice the sodium pentobarbitone was
injected immediately after the labelled IgG. At death the
spleens were removred into 10% formal saline. The tissues
were processed to paraffin blocks and for each mouse 5
sections prepared, one for haematoxylin and eosin (H&E)
staining and 4 for autoradiography (K2 emulsion, Ilford
Nuclear Emulsions, Knutsford, Cheshire). After an exposure
period of 14 days the ARGs were developed and stained
with H&E.
Tunmour-specific cntibody (MRC OX7) Examination of the
non-ARG H&E stained sections of the spleens from the 6
mice showed a typical pattern of murine T cell lymphoma
infiltration. The periarteriolar lymphoid sheath (PALS), a
domain of the normal T lymphocyte, was taken up by A120
lymphoblastic cells. Surrounding this sheath was a collar of
apparently normal lymphocytes, generally 5-10 cells deep.
The outer cells of this collar were immediately adjacent to
the marginal sinus (MS). A120 cells were also present singly
and in small clumps throughout the red pulp and in small
numbers in the blood stream. Macromolecules in the mouse
spleen leave the blood with ease through the highly
permeable walls of the marginal sinus, the marginal zone,
and the sinusoids of the red pulp (Moore et al., 1964;
Veerman & van Ewijk, 1975). It was therefore not surprising
on examination of the ARGs of the mice killed after Omin
to find moderate grain density (assumed to indicate the
presence of antibody) in the marginal zone and throughout
the red pulp. The highest grain count was seen immediately
over blood vessels. The cells surrounding the central arteriole
(CA) of the white pulp had no grain counts above
background. This indicated that the labelled antibody had
not diffused from the lumen of the CA either in the few
minutes between antibody injection and organ dissection, or
during the fixation, processing and ARG exposure of the
tissue.
After 30min the grain pattern in the ARGs had changed
(Figure Ia). In the red pulp clumps of tumour cells had
apparently attracted a large quantity of MRC OX7. In the
white pulp a clear circle of tumour cells with a similar level
of activity could be seen on the border between the tumour-
filled PALS and the surrounding collar of normal
lymphocytes. There was little activity above background
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Figure l(a) Autoradiograph of lymphoma-infiltrated mouse
spleen showing 3 areas of white pulp separated by red pulp. The
spleen was fixed 30min after i.v. injection of 125I-labelled MRC
OX7. Grains are seen over the first line of tumour cells
(arrowed) between the marginal sinus and the central arteriole
(C). The position of the marginal sinus is indicated at one point
by opposing arrow heads. The collar of normal white pulp
lymphocytes is marked by a bar. The high activity (dark grains)
in the red pulp (R) is mostly associated with tumour cells (H&E,
x 160). (b) Area similar to (a) 4h after the injection of 125[1
labelled MRC OX7. When compared with (a) it is seen that
tumour cells towards the central arteriole (C) have overlying
grains. The grain density is still low immediately around the
central arteriole. The position of the marginal sinus is indicated
by opposing arrow heads. (H&E, x 160).
associated with the cells lying between this ring of tumour
cells and the CA. Occasionally a cluster of grains indicated
the likely position of a capillary. The impression was gained
that binding sites on the outer ring of tumour cells were
competing successfully with the deeper cells for antibody
diffusing from the MS.
At 4h the ARG pattern in the red pulp had not changed
(Figure lb). However, in the white pulp there was accumula-
tion of antibody, as indicated by grains, on many more
tumour cells. It was noticeable that there was a falling grain
count from the outer ring of tumour cells to the CA and in
some PALs there were no grains above background for a
depth of up to 10 cells surrounding the CA.
Control, non-specific antibody (H]7E2) The spleen from the
2 mice killed at 0min after labelled H17E2 produced on
ARG an identical picture to the 0min mice injected with
MRC OX7. However, at 30min the non-specific antibody
was, as might be expected, not binding specifically to tumour
cells but was fairly uniformly distributed - unlike the 30min
mice given MRC OX7. In the interval from 30min to 4h
there was no change in distribution of labelled antibody and
there was no indication of a preferential retention of the
IgG1 by the lymphoma cells. The results from the control
animals support the hypothesis that it is the specificity of the
monoclonal antibody that causes it to be held by the tumour
cells nearest to the point of egress of the antibody from the
blood vessels.
A number of points have to be considered before drawing
tentative conclusions from this study and extrapolating the
data to other tumour systems. In any organ the drainage of
lymph from tissues becomes progressively disorientated by
infiltrating tumour and this makes the prediction of the
movement of tissue fluid and macromolecules in tumours
very difficult. In areas of loosely packed tumour cells it can
be predicted that antibody will diffuse relatively easily
between the cells even if there is no blood-to-lymph flow of
intercellular fluid (Swabb et al., 1974). However, in the
centre of a lymphoma follicle, or lymphoma-infiltrated
PALS, where the cells may not be loosely packed, the spread
of tumour-specific antibody by diffusion may well be
minimal because of the paucity of inter-cellular fluid. This is
not the only way that antibody movement may be restricted.
Where the McAb is of high affinity and the tumour cells
have a large number of binding sites it can be expected that
tumour cells closest to the point of egress from the
capillaries will compete effectively for antibody.
In the present experiments the IgG MRC OX7, had a high
affinity for Thy 1.1 (Mason & Williams, 1980). The tumour
cell surface epitope density was also high (Q- 3 xl0 cell-1).
We suggest that the net effect of this was that antibody
leaving the MS and diffusing towards the central arteriole
was avidly retained by the first tumour cells encountered. By
4 hours there had been some further centripetal movement
of antibody, but a gradient still existed from the MS to the
CA. Impedance to the free diffusion of antibody over the 4
hour period observed in the present study is most likely to
be a problem where the antibody is carrying a radoinuclide
of short half-life. If the impedance occurs for longer periods
of time implications for antibody targetted therapy could be
wider.
Although there are capillaries in the PALS carrying blood
from the CA to the white pulp and the MS, they are much
less permeable to macromolecules than are the vessels of the
MS and marginal zone. It is possible that in the present
experiments pressure caused by the expanding mass of A120
cells in the white pulp could have reduced the blood flow in
the capillaries in the white pulp. The 'alternative circulation'
(Veerman & van Ewijk, 1975) from the terminal
ramifications of the CA direct to the red pulp could in this
situation supply the MS and marginal zone.
Similar findings to ours have been observed in patients by
Gracia et al. (1985) following the treatment of lymphoma
with anti-idiotype McAb. These patients had a low-grade B
cell lymphoma and lymph nodes were sampled within 24
hours of anti-idiotype therapy. Frozen lymph node sections
exposed to FITC-labelled anti-mouse antibody revealed a
clear ring of tumour cells bearing mouse antibody at the
edge of the tumour follicles, again suggesting a preferential
retention by cells closer to the capillaries.
Our results and those of Gracia et al., indicate that there
can be a falling gradient of antibody away from the vessel of
egress. This does not exclude the possibility that given time
quite adequate levels of antibody-bound cytotoxin can be
transported to the tumour cells lying farthest from the blood
supply. It does however illustrate the necessity to look
further at the problem of movement of therapeutic
macromolecules through tumours where diffusion may be
strongly influenced by such things as histomorphologyv intra-
tumour pressure, intercellular fluid composition and
receptor/antigen density.
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